Bispecific HER2 × CD3 Antibodies Enhance T-Cell Cytotoxicity in Vitro and Localize to HER2-Overexpressing Xenografts in Nude Mice
- 1 February 1995
- journal article
- research article
- Published by Elsevier in Clinical Immunology and Immunopathology
- Vol. 74 (2) , 185-192
- https://doi.org/10.1006/clin.1995.1027
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- TARGETING HUMAN LYMPHOCYTES-T WITH BISPECIFIC ANTIBODIES TO REACT AGAINST HUMAN OVARIAN-CARCINOMA CELLS GROWING IN NU/NU MICE1990
- CHARACTERIZATION OF MURINE MONOCLONAL-ANTIBODIES REACTIVE TO EITHER THE HUMAN EPIDERMAL GROWTH-FACTOR RECEPTOR OR HER2 NEU GENE-PRODUCT1990
- Preliminary trial of specific targeting therapy against malignant gliomaThe Lancet, 1990
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.The Journal of Immunology, 1987
- Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.Proceedings of the National Academy of Sciences, 1987
- Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G 1 FragmentsScience, 1985
- The human lymphocyte function-associated (HLFA) antigen and a related macrophage differentiation antigen (HMac-1): functional effects of subunit-specific monoclonal antibodies.The Journal of Immunology, 1985
- Distinctive functional characteristics of human „T”︁ lymphocytes defined by E rosetting or a monoclonal anti‐T cell antibodyEuropean Journal of Immunology, 1981
- LIGAND: A versatile computerized approach for characterization of ligand-binding systemsAnalytical Biochemistry, 1980